Index removal puts Corcept Therapeutics in focus

Corcept Therapeutics (CORT) was recently removed from both the Russell 1000 Defensive Index and the Russell 1000 Growth-Defensive Index, an adjustment that can prompt trading shifts by index-tracking funds.

For existing and prospective shareholders, the move raises practical questions about how index-related flows might interact with Corcept Therapeutics’ current valuation, trading liquidity, and the company’s broader profile in the pharmaceuticals and biotechnology sector.

Against the backdrop of its index removal, Corcept Therapeutics’ recent 30 day share price return of 25.61% and 90 day share price return of 108.24% point to strong price momentum. The 1 year total shareholder return of 24.03% contrasts with a very large 3 year total shareholder return.

If you are weighing what else is moving in healthcare and biotech, this could be a good moment to scan other opportunities through our healthcare focused screener of 39 healthcare AI stocks

With Corcept Therapeutics now off key Russell indices yet showing strong recent share price momentum, investors are left weighing a familiar question: is the stock still undervalued, or is the market already pricing in future growth?

Most Popular Narrative: 1% Overvalued

Corcept Therapeutics last closed at $88.48, slightly above the most followed narrative fair value of $88, which anchors many of the current valuation debates.

The publication of the CATALYST study and the resulting increased awareness and screening for hypercortisolism among physicians are expanding the potential addressable patient pool, which is expected to drive significant acceleration in revenue growth over the next several years.

Read the complete narrative. Read the complete narrative.

Curious what kind of revenue and margin profile would justify that fair value for Corcept Therapeutics? The most followed narrative leans on rapid top line expansion, sharply higher profitability, and a future earnings multiple that looks very different from today.

Result: Fair Value of $88 (OVERVALUED)

However, investors in Corcept Therapeutics still need to watch for setbacks around Korlym patent litigation or any regulatory delays on relacorilant, as these could quickly challenge this narrative.

Another View on Corcept Therapeutics’ Value

While the most followed narrative has Corcept Therapeutics at roughly 1% over its $88 fair value, the SWS DCF model points to a slightly different picture, with an estimated future cash flow value of $89.78 and the stock trading about 1.4% below that level. For you, the question is whether a modest DCF gap is enough to offset concerns about execution and pricing risk.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Corcept Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 41 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If the mixed signals around Corcept Therapeutics leave you on the fence, take a closer look at the full picture now and shape your own stance with the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Corcept Therapeutics?

If Corcept Therapeutics has you thinking more broadly about opportunities, use this moment to widen your radar with other stocks that fit clear, disciplined criteria.

• Spot potential mispricings early by scanning companies that combine quality fundamentals with appealing valuations through our 41 high quality undervalued stocks.
• Build a portfolio that aims for resilience first by checking companies with stronger balance sheets and fundamentals using the solid balance sheet and fundamentals stocks screener (47 results).
• Get ahead of the crowd by reviewing financially sound businesses that are still flying under many investors' radars in our screener containing 19 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.